Zhejiang Provincial Key Laboratory for Drug Clinical Research and Evaluation, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.
Virol J. 2020 Aug 24;17(1):127. doi: 10.1186/s12985-020-01404-z.
There has been little published data on estimates of HBV and/or HCV coinfection in HIV-positive patients in China or an understanding of how this coinfection varies with different factors. Therefore, this study aimed to determine, through a systematic review and meta-analysis, the prevalence of HBV and/or HCV in HIV-positive patients in China and explore variations in prevalence.
The Medicine, Web of Science, Chinese Web of Knowledge, and Wanfang databases were searched using a search strategy combining key words and related disease-specific subject terms to identify relevant cohort or cross-sectional studies published up to April 2019. Included articles were assessed for quality. Pooled prevalence and 95% confidence intervals (CIs) were calculated according to study region and other specific characteristics.
Our searches identified 7843 records, but only 66 studies were included in our meta-analysis. The pooled HBsAg prevalence in HIV-positive patients was 13.7% (95% CI 12.3-15.3%), with variations found in terms of age and geographic region. The meta-HCV prevalence was 24.7% (95% CI 19.3-30.5%), which varied over the study period and age. The pooled HBV-HCV coinfection prevalence was 3.5% (95% CI 2.4-4.8%), with variations found in terms of age and geographic region.
Given the high burden of HBV and HCV coinfections in HIV-positive patients, the incorporation of comprehensive screening, treatment, prevention, and vaccination programs into general HIV management in China is imperative.
中国有关 HIV 阳性患者中 HBV 和/或 HCV 合并感染的估计数据很少，也不了解这种合并感染如何随不同因素而变化。因此，本研究旨在通过系统评价和荟萃分析，确定中国 HIV 阳性患者中 HBV 和/或 HCV 的流行率，并探讨流行率的变化。
采用结合关键词和相关疾病特定主题词的搜索策略，检索医学、Web of Science、中国知识网和万方数据库，以确定截至 2019 年 4 月发表的相关队列或横断面研究。对纳入的文章进行质量评估。根据研究区域和其他特定特征，计算合并流行率和 95%置信区间（CI）。
我们的搜索共确定了 7843 条记录，但只有 66 项研究纳入荟萃分析。HIV 阳性患者的 HBsAg 总流行率为 13.7%（95%CI 12.3-15.3%），不同年龄和地理区域之间存在差异。荟萃 HCV 流行率为 24.7%（95%CI 19.3-30.5%），研究期间和年龄不同。HBV-HCV 合并感染的总流行率为 3.5%（95%CI 2.4-4.8%），不同年龄和地理区域之间存在差异。
鉴于 HIV 阳性患者中 HBV 和 HCV 合并感染的负担很重，因此中国必须将全面的筛查、治疗、预防和疫苗接种计划纳入 HIV 综合管理中。
Zotero 插件
